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OBJECTIVE—To compare the effect of intensive versus standard glycemic control strategies
on health-related quality of life (HRQL) in a substudy of the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial.
RESEARCH DESIGN AND METHODS—A randomly selected subsample of 2,053
ACCORD participants enrolled in the HRQL substudy was assessed at baseline and 12-, 36-, and
48-month visits. HRQL assessment included general health status (the 36-Item Short Form Health
Survey[SF-36]),diabetessymptoms(theDiabetesSymptomDistressChecklist),depression(Patient
Health Questionnaire [PHQ]-9), and treatment satisfaction (Diabetes Treatment Satisfaction Ques-
tionnaire [DTSQ]). Repeated-measures ANOVA models were used to estimate change in HRQL
outcomes by treatment group over 48 months adjusting for model covariates. The effects of early
discontinuation of the ACCORD intensive glycemic control arm on study results were explored.
RESULTS—A total of 1,956 (95%) completed the self-report HRQL instrument(s) at baseline.
The intensive arm had a larger decrease in SF-36 physical health component score than the
standard arm (21.6 vs. 21.1, P = 0.0345). Treatment satisfaction (DTSQ) showed larger im-
provement with intensive than standard (P = 0.0004). There were no differences in mean scores
of the Diabetes Symptom Checklist and PHQ-9. Effects of participant transition following dis-
continuation of the intensive arm on HRQL were not signiﬁcant.
CONCLUSIONS—The ACCORD trial strategy of intensive glycemic control did not lead to
beneﬁts in HRQL and was associated with modest improvement in diabetes treatment satisfac-
tion. Thus patient acceptability was apparently not compromised with intensive and complex
interventions such as those used in ACCORD.
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T
he Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study
was a multicenter randomized con-
trolled treatment trial testing indepen-
dent effects of two strategies of control
of blood glucose, blood pressure, and
lipids on cardiovascular disease (CVD) in
patients with type 2 diabetes (1). The gly-
cemia trial randomized 10,251 partici-
pants with type 2 diabetes to intensive
(goal HbA1c ,6%) or standard therapies
(goal HbA1c 7.0–7.9%). All participants
were also randomized to the blood pres-
sure or lipid trial arms. An ACCORD sub-
study focused on health-related quality
of life (HRQL) outcomes associated with
intensive versus standard glycemic con-
trol strategies (2). The rationale for the
HRQL substudy was the need to consider
the impact or potential beneﬁt of inten-
sive glycemia management from the par-
ticipants’ point of view. Diabetes is
known to be associated with decrements
in HRQL from functional limitations,
restrictionsinnormalactivities,worklim-
itations, poor general health, and depres-
sion (3–6) and from symptom distress
such as excessive thirst, frequent urina-
tion, fatigue, and neuropathies (7–11).
Patients with diabetes commonly suffer
from psychological disturbances such as
depression, anxiety, and social with-
drawal (12,13). Thus potential treatment
beneﬁts of improved diabetes control and
reduced risk for vascular diseases could
have broad HRQL beneﬁt. Short-term ef-
fects of HbA1c level on HRQL have been
reliably shown (3); however, few longitu-
dinal studies have examined HRQL in the
contextofintensiveglycemiccontrol.The
potential impact of treatment complexity
on daily life with diabetes is also impor-
tant to consider (5,14,15). In ACCORD
the intensive glycemia target of HbA1c
,6% places a greater burden on the pa-
tient in terms of self-management, phar-
macologic intensiﬁcation, and ofﬁce
visits. Additionally the potential for side
effects must be weighed. Thus this report
addresses a secondary objective of the
ACCORD trial to investigate the effects
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ORIGINAL ARTICLEof glycemic control strategy on patient
appraisal of general health, symptoms,
depression, and treatment satisfaction.
RESEARCH DESIGN AND
METHODS—The ACCORD glycemia
treatment trial methods and design have
been previously reported (16,17). Brieﬂy,
this was a randomized controlled clinical
trial of treatment for type 2 diabetes, con-
ductedin77clinicalcentersacrosstheU.S.
and Canada. Central laboratory measures
of HbA1c were used to reﬂect level of gly-
cemic control. A total of 10,251 partici-
pants were recruited and randomly
assigned to either intensive glycemia man-
agement with a target HbA1c ,6.0% or
standard glycemia management with a tar-
get HbA1c between 7.0 and 7.9%. To be
eligible for ACCORD, participants had to
have a conﬁrmed diagnosis of type 2 dia-
betes; an HbA1c between $7.5 and 11%;
and be either 1)a g e4 0 –79 years with car-
diovascular disease or 2)a g e5 5 –79 years
withanatomicalevidenceofsigniﬁcantath-
erosclerosis, albuminuria, left ventricular
hypertrophy, or at least two additional
risk factors for CVD (dyslipidemia, hyper-
tension,current status as a smoker,orobe-
sity). Key exclusion criteria included
frequent or recent serious hypoglycemic
events, unwillingness to do home glucose
monitoringorinjectinsulin,aBMIofmore
than 45 kg/m
2, a serum creatinine level of
greater than 1.5 mg/dL, or other serious
illness. The ACCORD study protocols
were approved by the institutional review
board or ethics committee at each
ACCORD site or coordinating center as
well as by an ethics review panel at the Na-
tional Heart, Lung, and Blood Institute. All
patientsprovidedwritteninformedconsent.
HRQL substudy
The ACCORD HRQL study was designed
to detect meaningful change from base-
line in HRQL associated with glycemic
control treatment arms. Speciﬁcally, the
prespeciﬁed objectives were to test po-
tential treatment beneﬁts from intensive
glycemicversusstandardtherapyinterms
of less symptom distress, improved gen-
eral health (physical and psychological
wellbeing), and improved treatment sat-
isfaction. The impact of the intervention
on depression, based on data from the
Patient Health Questionnaire (18), is re-
ported here as a secondary outcome.
Of the 10,251 patients enrolled in the
ACCORD trial, a randomly selected sub-
sample of 2,053 was enrolled in the
ACCORD HRQL substudy. Of these,
N = 1,024 had been randomized to inten-
sive glycemic control and N =1 , 0 2 9t o
standard control.
Study outcomes and covariates
Four distinct measures, general health,
treatment satisfaction, diabetes-related
symptoms, and depression, were used to
measure HRQL. Data were collected by
self-report questionnaire administered at
the ACCORD baseline, 12-, 36-, and 48-
month visits. General health status was
assessed using the 36-Item Short Form
Health Survey, Version 2 (SF-36) (19),
where aggregate physical health (PH)
and mental health (MH) component
scores were calculated. The component
scores are weighted combinations of in-
dividual items and have a general popu-
lation norm of 50 and a standard
deviation of 10, with higher scores repre-
senting better health. The PH component
refers to ratings of limitations in physical,
social, and role activities; severe bodily
pain; fatigue; and self-rated health. The
MHcomponentreferstopsychologicaldis-
tress, social and role disability as a result of
emotional problems, and self-rated health.
A 60-item version of the Diabetes
Symptoms Distress Checklist (DSC) (7)
wasusedtoassessthepresenceandseverity
(impact on functional status) of diabetes-
related symptoms. Participants report
whether or not they had experienced the
given symptom or feeling and rate symp-
tomdistressonascaleof0–4(0=notatall,
1 = somewhat, 2 = moderately, 3 = very
much, 4 = extremely).
Satisfaction with diabetes treatment
was assessed using the eight-item World
Health Organization Diabetes Treatment
Satisfaction Questionnaire (WHO-DTSQ),
an authorized version identical to the
DTSQ status version widely used in di-
abetes clinical trials (20). The DTSQ in-
cludes an overall six-item measure of
satisfaction with the diabetes regimen
with scores ranging from 0 to 36, with
higherscoresindicatinghighersatisfaction.
Forasubsetofparticipants(ACCORDvan-
guard phase), only ﬁve satisfaction items
were measured; therefore we converted
the DTSQ score to a range from 0 to 100.
In addition to the six-item measure, there
were also two standard questions assessing
perceived frequency of hyperglycemia and
hypoglycemia ranging from 0 to 6, with
higherscoresindicatingmorefrequentper-
ception of high or low blood glucose.
Depression was assessed using the 9-
item depression measure from the Patient
HealthQuestionnaire(PHQ-9).ThePHQ-9
is the self-report version of the PRIME-
MD,awell-validatedpsychiatricdiagnostic
interview for use in primary care settings
(18).Scoresrangefrom0–27,andthescore
is treated as a continuous variable.
Data analysis
All statistical analyses were conducted
using SAS software Version 9 (SAS In-
stitute, Cary, NC). Statistical signiﬁcance
wasdeﬁnedasPvalue,0.05.Descriptive
analyses of baseline clinical and HRQL
characteristics were used to assess the
representativeness of the HRQL subsam-
pleinrelationtotheACCORDstudypop-
ulation and to illustrate successful
randomizationoftheHRQLsubstudypar-
ticipants. Baseline characteristics of the
two study groups were compared using
x
2 tests, t tests, and Wilcoxon tests.
To examine the effects of glycemic
control treatment arm before the end of
the glycemia trial on study outcomes
of general health, treatment satisfaction,
diabetes-relatedsymptoms,anddepression,
each outcome measure was considered in
three separate sets of repeated-measures
linear models. We used data up until
5 February 2008, when the ACCORD
glycemia trial was stopped. Each set mod-
eledthechangeintheHRQLmeasure,and
each set included the following terms:
glycemia intervention, secondary trial as-
signment, prior CVD at baseline, the
baseline HRQL measure, time, and a
time-by-glycemia interaction term. A ﬁrst
set, as speciﬁed in the protocol, included
only these measures. The second set
added age, race, and sex. The ﬁnal set
added the set of covariates listed above.
We report the overall test of the glyce-
mia term across all visits. We visually
examined the estimated change in HRQL
measure across the three time points in
plots. Because it is possible that intensive
glucose control increases, decreases, or
leaves unchanged patients’ HRQL, we
used two-sided P values to determine sta-
tistical signiﬁcance as is conventional in
clinical trial reports. Our prespeciﬁed
a-level was 0.05. Although no formal ad-
justments for multiple comparisons were
made,giventhenumberoftestsperformed
we estimate the probability of ﬁnding at
least one model with a P value less than
0.05 to be 70.5%.
Early discontinuation of ACCORD
intensive glycemia treatment
The glycemia intervention of ACCORD
study was stopped early on 5 February
2008 because of higher mortality in the
intensive group (21). All patients were
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ACCORD glycemia trial and quality of lifetransitioned to the standard glycemia-
regimen and continued in the ACCORD
blood-pressure and lipid studies for their
planned durations of at least 4 years of
follow-up. To assess potential effects of
the transition to standard therapy on
HRQL outcomes, we conducted an addi-
tional set of analyses including the HRQL
data collected after the end of the glycemia
trial.Notallparticipantshadpost-transition
HRQL measures, and those that did have
measures were at the months 36 and
48 visits. We added a term to the model
to indicate whether the measure was post-
transition and added an interaction term
for post-transition and glycemia arm.
RESULTS
Baseline sample characteristics
Table 1 presents the characteristics of the
2,053 participants who were included in
the ACCORD HRQL substudy. There
werenostatisticallysigniﬁcantdifferences
in any of the characteristics examined by
studysample. Clinical statusoftheHRQL
substudy group at baseline was a mean
HbA1c of 8.3 6 1%; means for weight
and BMI were 94 kg and 32 kg/m
2,r e -
spectively,and theaveragedurationofdi-
abetes was 10 years (vs. 9 years in those
not in the HRQL study, P = 0.0536), with
;3 7 %a l r e a d yo na ni n s u l i nt r e a t m e n t
regimen at baseline. A comparison of
Table1covariatesonACCORDtreatment
group status of intensive glycemia (goal
HbA1c ,6%) versus standard therapy
(goal HbA1c 7.0–7.9%) found no statisti-
cally signiﬁcant results (data not shown).
Among ACCORD HRQL study par-
ticipants, the analytic sample included
1,956(95%)who completed one or more
instruments within the baseline HRQL as-
sessments (974/1,024 for intensive glyce-
mia, and 982/1,029 for standard therapy).
Sample sizes available for repeated-
measures analysis of the HRQL follow-
upat12,36,and48monthswereN=92 1,
N = 549, and N = 208 for intensive treat-
ment and N = 937, N = 583, and N = 208
for standard therapy.
Table 2 presents baseline HRQL
scores by ACCORD glycemia treatment
group status. At baseline, ACCORD
HRQL study participants reported lower
physical health (PH component score)
than the general population norm of
50.0 (means = 38.0 and 37.4 per treat-
mentgroup),whereaspsychologicalwell-
being was similar to the general
population norm of 50.0 reported by
Wareet al.(19).HRQLstudy participants
in the intensive treatment group had sta-
tistically signiﬁcantly higher physical
healthcomponentscoremean(i.e.,some-
what better HRQL) and lower (i.e., some-
what worse) MH component score mean
than those assigned to standard therapy,
although these differences were very
small. The mean number of nonzero
diabetes-related symptoms assessed on
the Diabetes Symptoms Distress Checklist
total symptoms reported in the intensive
and standard glycemia treatment groups
was 17.2 and 16.9, respectively, with a
mean symptom distress rating of ;1.5,
or the midpoint in the scale between
somewhatandmoderately.Forthepurpo-
ses of this study, diabetes treatment satis-
faction assessed with the DTSQ treatment
satisfaction scale, transformed to a per-
centage scale (0 to 100), was 72.5 vs.
74.0 and for the single item frequency rat-
ings was a mean of ;1.3 for perceived
hypoglycemia and 3.6 for perceived hy-
perglycemia.
Results for the general linear models
forrepeatedmeasuresfortheHRQLstudy
outcomes through the active glycemia
intervention are presented in Table 3.
The results from the prespeciﬁed analy-
ses, adjusted only for trial assignment
and stratiﬁcation variables, did not vary
substantially from the results from a fully
adjusted model including a variety of
baseline covariates. After controlling for
baseline covariates, change in HRQL
over the 48-month duration in-trial was
statistically signiﬁcant for the SF-36 PH
component, and DTSQ treatment satis-
faction scale. For physical health, the in-
tensive glycemic control arm had a slight
(0.5point)reductioninmeanPHcompo-
nent change score (i.e., lowered HRQL)
relative tothose in the standard treatment
arm (21.6 vs. 21.1; P = 0.0345). For
treatment satisfaction, DTSQ scores
were signiﬁcantly higher (i.e., greater sat-
isfaction) than basel i n ei nb o t hg r o u p s ,
with a larger improvement in satisfaction
Table 1—Baseline characteristics of ACCORD participants by ACCORD HRQL
substudy status
Baseline characteristics
HRQL substudy
P value Yes No
N 2,053 7,583
Mean age (years) 62.2 6 6.7 62.1 6 6.8 0.5454
Women (%) 39.6 38.4 0.3171
Non-Hispanic white (%) 65.1 64.5 0.6520
Black (%)* 19.5 19.1 0.6818
Hispanic (%)* 6.8 7.3 0.3829
Highest level of education 0.5130
High school 13.9 14.8
High school graduate or equivalent 26.0 26.7
Some college or college graduate 60.1 58.5
Living with someone (%) 80.0 79.7 0.7713
Drinking (%) 22.5 24.1 0.1358
Cigarette smoker (%) 0.1973
Current 13.3 14.5
Previous 45.6 43.7
Never 41.2 41.9
Mean HbA1c (%) 8.3 6 1.1 8.3 6 1.0 0.5014
Median HbA1c (%) 8.1 8.1 0.5712
Mean fasting plasma glucose (mg/dL) 177.1 6 57.5 174.9 6 56.0 0.1266
Median duration of diabetes (years) 10 9 0.0536
On insulin (%) 35.9 34.8 0.3233
Mean weight (kg) 94.1 6 18.9 93.6 6 18.6 0.2735
BMI (kg/m) 32.4 6 5.5 32.3 6 5.5 0.2153
Waist circumference (cm) 107.1 6 13.9 106.8 6 13.9 0.4899
Peripheral neuropathy (%) 43.0 42.6 0.7782
Macroalbuminuria (%) 7.3 6.3 0.1266
Microalbuminuria (%) 30.1 31.4 0.2395
Mean SBP (mmHg) 136.2 6 17.1 136.2 6 17.2 0.8398
Mean DBP (mmHg) 74.5 6 10.9 75.0 6 10.6 0.0837
SBP, systolic blood pressure; DBP, diastolic blood pressure.
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Anderson and Associateswith the treatment regimen (2.4 points;
P = 0.0004) in the intensive arm. DTSQ
single-item ratings of satisfaction with
high and low blood glucose showed that
participants in the intensive arm reported
perceived improved (less) frequency of
high blood glucose (21.7 unit reduction
frombaseline,P,0.0001),butperceived
frequency of hypoglycemia was increased
(0.8 unit increase from baseline, P ,
0.0001).
Results for all time points grouped as
pretransition and post-transition to the
ACCORD standard glycemia-regimen and
all data collected (not shown) revealed
similar treatment group outcomes as the
in-trialperiodresultsshowninTable3,but
with a somewhat larger improvement in
mean DTSQ treatment satisfaction means
intheintensivetreatmentgroup(pretransi-
tion: 20.8 vs. 20.8; post-transition: 20.8
vs. 21.2 for standard vs. intensive treat-
ment groups, respectively). The difference
between groups in the SF-36 PH and MH
componentswasnotstatisticallysigniﬁcant
(P =0 . 1 2 7 9a n dP = 0.1414, respectively).
Groupandtransition(prepost)interactions
for the HRQL outcomes were also tested,
and none of the P values for interaction
terms reached statistical signiﬁcance.
CONCLUSIONS—The ACCORDtrial
included HRQL as a secondary objective
to more fully understand the potential
beneﬁts of intensive glycemic control
through the patient’s point of view. After
baseline HRQL status and clinical covari-
ates in repeated-measures analysis were
controlled, the results obtained for
change in HRQL over a 48-month obser-
vation period after randomization did not
show meaningful beneﬁt between inten-
sive glycemic control as compared with
standard glycemic control strategies in
domains of general health, diabetes
symptoms, or depression. The pattern of
no intensive treatment beneﬁto nH R Q L
is consistent with the results for the
ACCORD main study (1) of lack of car-
diovascular beneﬁt from intensive glyce-
mia treatment with a target of HbA1c
,6%. There were no demonstrated ef-
fects upon MH simply from improved
glycemic control in the intensive arm. Al-
though there is some evidence in the lit-
erature of modest beneﬁts to emotional
wellbeing from improved glycemia, stud-
ies are mixed plausibly because of treat-
ment variation and approach (22). In
ACCORDbothtreatmentarmshadtargets
ofimprovedglycemiccontrol,withthein-
tensive arm designed to achieve greater
control albeit with potentially greater
treatment complexity. Although the SF-
36 PH component score was signiﬁcantly
different between groups, the absolute net
difference of 0.5 units of change is trivial
andwellbelowageneralthresholdof;3–
5 points for a minimally important differ-
ence on thesemeasures (19) and therefore
clinically insigniﬁcant. The pattern of re-
sultsindicatesthatforallHRQLstudyout-
come measures considered, with the
exception of treatment satisfaction (which
had a trend toward increased satisfaction),
there was a pattern of stability over time in
scores for both treatment groups. The SF-
36 PH and MH component scores were
preplanned HRQL outcome measures in
this study. A post hoc analysis of the eight
individual SF-36 scale score means explor-
ing the consistency of effects among the
HRQL concepts that comprise the SF-36
component scores revealed no unusual or
inconsistent inﬂuences on these summary
component scores.
The ﬁnding of no decrement in treat-
ment satisfaction, either when compared
with those in standard treatment arm or
over time, is notable because one source
of reluctance in initiating intensive treat-
ment regimens like the ACCORD inter-
vention is reasonable concern over
patient burden. The lack of decrement
in subjective wellbeing particularly in the
context of intensive glucose treatment
may be related to several processes. There
was increased accesstoproviders, includ-
ing both clinic visits and telephone con-
tact in the intensive treatment arm. This
mayhaveincreasedperceivedcarequality
and may have supported patient self-
efﬁcacy for managing diabetes. Patients’
perception of optimal HbA1c control in
the intensive control arm, which sought
to lower HbA1c to , 6%, may also have
been important in this regard. Research
on treatment satisfaction in diabetes has
s h o w nt h a th a v i n gi m p r o v e db l o o dg l u -
cose or HbA1c levels is an important
driver of satisfaction regardless of treat-
ment intensity (23,24) and may inﬂuence
patient appraisals of treatment effective-
ness. Thus the results from this study
add to the literature on treatment inten-
sity, ﬁnding that patients may perceive
intensive treatment as favorable. The ﬁnd-
ing that patients perceived hyperglycemia
as a bigger problem than hypoglycemia
may indicate the relative importance pa-
tientsattachtohyperglycemiaversushypo-
glycemia.
The early stopping of the ACCORD
intensiveglycemiccontrolarmresultedin
the transition of the intensively treated
participantstostandard glycemiccontrol.
Analysis examining HRQL outcomes of
data up to glycemia trial discontinuation
on 5 February 2008 and all data through
to ﬁnal follow-up showed that results
werehighlysimilarpre-andpost-transition.
Death and trial inactivity were censoring
events in this repeated-measures analysis
by dictating the last valid HRQL assess-
ment point entered into analysis (last
observation carried forward). In the
HRQL study sample there were a total of
78 deaths over the study period; 25 of
theseeventsresultedinnovaluableHRQL
information (all time points missing); in
44 events, HRQL baseline and 12-month
informationwas possibletocollect, and in
nine events all but the 48-month HRQL
assessment was possible to collect. We
examined baseline status predictors of
death or inactivity in the HRQL sample
from standard demographic status, life-
style, comorbidity, diabetes, and bio-
marker variables. Results found higher
frequency of either death or inactivity
(events) was associated with older age,
being a current smoker, living alone,
Table 2—Baseline HRQL values by ACCORD glycemia arm
Baseline HRQL measure
Glycemia arm
P value N Standard mean N Intensive mean
SF-36 physical component score
a 975 37.4 966 38.0 0.0192
SF-36 mental component score
a 975 53.4 966 52.1 0.0197
DSC total symptom score
b 978 16.9 973 17.2 0.5654
DSC symptom distress 966 1.5 954 1.5 0.6047
DTSQ treatment satisfaction scale
c 966 74.0 953 72.5 0.1016
DTSQ perceived hypoglycemia
d 976 1.2 969 1.3 0.6403
DTSQ perceived hyperglycemia
d 978 3.6 970 3.6 0.5901
PHQ-9 depression
d 981 5.2 972 5.6 0.0816
aHigher SF-36 component scores signify better HRQL;
bDSC;
cDTSQ transformed to scale of 0–100;
dDTSQ
ratings of hyperglycemia and hypoglycemia (range: 6 [most of time] to 0 [none of time]).
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ACCORD glycemia trial and quality of lifealbuminuria,anddiastolicbloodpressure.
In a secondary analysis (data not shown)
that included predictors of events pro-
duced highly similar results to the formal
analysis presented above.
There areseveral potentiallimitations
to consider when interpreting these data
or ﬁndings. Our sample is not represen-
tative of the entire population of patients
with type 2 diabetes. ACCORD partici-
pants had a mean age of 62, diabetes
duration of 10 years, risk factors for
CVD, a baseline HbA1c $7.5%, and will-
ingness to undergo intensive treatment to
control glucose, including frequent clinic
visits and the use of insulin. Although we
assessed a broad range of factors for their
associations with HRQL, there are many
other factors that could have been exam-
ined,especiallyinbehavioralandpsycho-
social domains that may have been more
responsive to potential burdens or risks
withintensiveglycemiccontrolstrategies.
For example, our study did not include
covariates concerning emotional state,
mood, locus of control, social support,
or others (5,25), limiting our ability to
comment on the role of these inﬂuences.
For the DTSQ measure, during ACCORD
vanguard, which enrolled 1,184 patients,
item 8 (recommend treatment to others)
was not assessed in either treatment
group. Given the high internal consis-
tency reliability of the DTSQ (a .0.85)
we believe that this item omission in a
subset of patients wouldhave littleappre-
ciable impact on the estimated treatment
effect for this outcome. Finally, although
we included known correlates of death
and participant study inactivity in our
models to limit their inﬂuence in treat-
ment group comparisons, this step could
not remove all potential sources of bias
and neither would the alternative of im-
puting missing values. We studied sub-
jective, self-reportedh e a l t ha p p r a i s a lo f
participants. A health utility measure-
ment model is an alternative approach
that allows for the outcome of death to
be incorporated in health scores. We nei-
ther planned nor examined a utility
model with these data.
Insummary, thisstudy demonstrated
nosigniﬁcantHRQLbeneﬁtorharmfrom
the ACCORD intensive glycemic control
strategies. Participants in the intensive
treatment arm reported a greater increase
in satisfaction with their diabetes treat-
ment. The latter result suggests that new
or emerging treatment strategies in di-
abetesthatarebothintensiveandsafecould
be perceived by patients as worthwhile
T
a
b
l
e
3
—
R
e
s
u
l
t
s
o
f
r
e
p
e
a
t
e
d
-
m
e
a
s
u
r
e
s
a
n
a
l
y
s
e
s
o
f
H
R
Q
L
o
u
t
c
o
m
e
s
b
y
g
l
y
c
e
m
i
a
a
r
m
a
n
d
c
h
a
n
g
e
i
n
s
c
o
r
e
f
r
o
m
b
a
s
e
l
i
n
e
a
c
r
o
s
s
a
l
l
v
i
s
i
t
s
V
a
r
i
a
b
l
e
P
r
e
s
p
e
c
i
ﬁ
e
d
a
n
a
l
y
s
i
s
i
n
p
r
o
t
o
c
o
l
e
F
u
l
l
y
a
d
j
u
s
t
e
d
m
o
d
e
l
f
S
t
a
n
d
a
r
d
I
n
t
e
n
s
i
v
e
T
e
s
t
S
t
a
n
d
a
r
d
I
n
t
e
n
s
i
v
e
T
e
s
t
E
s
t
i
m
a
t
e
g
9
5
%
C
I
E
s
t
i
m
a
t
e
g
9
5
%
C
I
P
v
a
l
u
e
E
s
t
i
m
a
t
e
g
9
5
%
C
I
E
s
t
i
m
a
t
e
g
9
5
%
C
I
P
v
a
l
u
e
S
F
-
3
6
p
h
y
s
i
c
a
l
c
o
m
p
o
n
e
n
t
s
c
o
r
e
2
0
.
2
(
2
0
.
5
t
o
2
0
.
2
)
2
0
.
7
(
2
1
.
1
t
o
2
0
.
4
)
0
.
0
2
4
2
2
1
.
1
(
2
2
.
0
t
o
2
0
.
2
)
2
1
.
6
(
2
2
.
5
t
o
2
0
.
7
)
0
.
0
3
4
5
S
F
-
3
6
m
e
n
t
a
l
c
o
m
p
o
n
e
n
t
s
c
o
r
e
2
0
.
3
(
2
1
.
0
t
o
0
.
4
)
0
.
2
(
2
0
.
6
t
o
0
.
9
)
0
.
3
3
6
1
0
.
8
(
2
1
.
0
t
o
2
.
6
)
1
.
4
(
2
0
.
5
t
o
3
.
2
)
0
.
2
9
3
8
D
S
C
t
o
t
a
l
s
y
m
p
t
o
m
s
c
o
r
e
a
2
1
.
2
(
2
1
.
7
t
o
2
0
.
6
)
2
0
.
6
(
2
1
.
2
t
o
2
0
.
1
)
0
.
2
0
5
1
2
0
.
4
(
2
1
.
9
t
o
1
.
0
)
0
.
1
(
2
1
.
4
t
o
1
.
6
)
0
.
1
9
4
0
D
S
C
s
y
m
p
t
o
m
d
i
s
t
r
e
s
s
0
.
0
(
2
0
.
1
t
o
0
.
0
)
0
.
0
(
2
0
.
0
t
o
0
.
0
)
0
.
2
3
1
9
2
0
.
1
(
2
0
.
2
t
o
0
.
0
)
0
.
0
(
2
0
.
1
t
o
0
.
1
)
0
.
1
5
1
2
D
T
S
Q
t
r
e
a
t
m
e
n
t
s
a
t
i
s
f
a
c
t
i
o
n
s
c
a
l
e
b
1
1
.
8
(
1
0
.
9
–
1
2
.
8
)
1
4
.
0
(
1
3
.
1
–
1
5
.
0
)
0
.
0
0
1
1
1
1
.
1
(
8
.
6
–
1
3
.
5
)
1
3
.
5
(
1
1
–
1
5
.
9
)
0
.
0
0
0
4
D
T
S
Q
p
e
r
c
e
i
v
e
d
h
y
p
e
r
g
l
y
c
e
m
i
a
c
2
0
.
9
(
2
1
.
0
t
o
2
0
.
8
)
2
1
.
4
(
2
1
.
5
t
o
2
1
.
3
)
,
0
.
0
0
0
1
2
1
.
2
(
2
1
.
5
t
o
2
0
.
9
)
2
1
.
7
(
2
2
.
0
t
o
2
1
.
5
)
,
0
.
0
0
0
1
D
T
S
Q
p
e
r
c
e
i
v
e
d
h
y
p
o
g
l
y
c
e
m
i
a
c
0
.
3
(
0
.
2
–
0
.
4
)
0
.
7
(
0
.
6
–
0
.
8
)
,
0
.
0
0
0
1
0
.
4
(
0
.
1
–
0
.
6
)
0
.
8
(
0
.
5
–
1
.
0
)
,
0
.
0
0
0
1
P
H
Q
-
9
c
o
n
t
i
n
u
o
u
s
s
c
o
r
e
d
2
0
.
8
(
2
1
.
1
t
o
2
0
.
6
)
2
0
.
7
(
2
0
.
9
t
o
2
0
.
4
)
0
.
4
5
9
4
2
1
.
0
(
2
1
.
7
t
o
2
0
.
4
)
2
0
.
9
(
2
1
.
5
t
o
2
0
.
3
)
0
.
4
4
1
4
a
D
S
C
;
b
W
H
O
D
T
S
Q
t
r
a
n
s
f
o
r
m
e
d
t
o
s
c
a
l
e
o
f
0
–
1
0
0
;
c
D
T
S
Q
r
a
t
i
n
g
s
o
f
h
y
p
e
r
g
l
y
c
e
m
i
a
a
n
d
h
y
p
o
g
l
y
c
e
m
i
a
(
r
a
n
g
e
:
6
[
m
o
s
t
o
f
t
i
m
e
]
t
o
0
[
n
o
n
e
o
f
t
i
m
e
]
)
;
d
P
H
Q
;
e
a
s
s
p
e
c
i
ﬁ
e
d
i
n
p
r
o
t
o
c
o
l
i
n
c
l
u
d
e
s
a
d
j
u
s
t
m
e
n
t
f
o
r
t
h
e
s
t
r
a
t
i
ﬁ
c
a
t
i
o
n
v
a
r
i
a
b
l
e
s
a
t
r
a
n
d
o
m
i
z
a
t
i
o
n
,
s
e
c
o
n
d
a
r
y
t
r
i
a
l
,
a
n
d
s
e
c
o
n
d
a
r
y
t
r
i
a
l
a
s
s
i
g
n
m
e
n
t
;
f
a
d
j
u
s
t
e
d
f
o
r
p
r
e
v
i
o
u
s
C
V
D
,
s
e
c
o
n
d
a
r
y
t
r
i
a
l
,
s
e
c
o
n
d
a
r
y
t
r
i
a
l
a
s
s
i
g
n
m
e
n
t
,
a
g
e
,
r
a
c
e
,
s
e
x
,
d
u
r
a
t
i
o
n
o
f
d
i
a
b
e
t
e
s
,
s
m
o
k
i
n
g
,
l
i
v
i
n
g
a
l
o
n
e
,
w
e
i
g
h
t
,
w
a
i
s
t
c
i
r
c
u
m
f
e
r
e
n
c
e
,
B
M
I
,
b
a
s
e
l
i
n
e
H
b
A
1
c
,
f
a
s
t
i
n
g
b
l
o
o
d
g
l
u
c
o
s
e
,
S
B
P
a
n
d
D
B
P
,
h
e
a
r
t
r
a
t
e
,
n
e
u
r
o
p
a
t
h
y
,
r
e
t
i
n
a
l
s
u
r
g
e
r
y
,
m
a
c
r
o
-
a
n
d
m
i
c
r
o
a
l
b
u
m
i
n
u
r
i
a
,
i
n
s
u
l
i
n
,
s
u
l
f
o
n
y
l
u
r
e
a
s
,
t
h
i
a
z
o
l
i
d
i
n
e
d
i
o
n
e
,
b
-
b
l
o
c
k
e
r
s
,
a
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
m
e
d
i
c
a
t
i
o
n
,
a
n
d
t
r
i
g
l
y
c
e
r
i
d
e
s
;
g
l
e
a
s
t
s
q
u
a
r
e
s
m
e
a
n
e
s
t
i
m
a
t
e
d
a
t
t
h
e
m
e
a
n
v
a
l
u
e
o
f
a
l
l
c
o
n
t
i
n
u
o
u
s
c
o
v
a
r
i
a
t
e
s
a
c
r
o
s
s
a
l
l
t
i
m
e
p
o
i
n
t
s
.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, APRIL 2011 811
Anderson and Associatesand that treatment acceptability is not a
limiting factor in complex interventions
such as ACCORD.
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